Home
EXEL
EXEL News

Latest Exelixis Inc. (EXEL) News on November 17, 2024

Argus Research

5 days ago

EXEL: Rating increased to a BUY

ADMA Biologics Inc (ADMA) Hits Fresh High: Is There Still Room to Run?

Zacks

5 days ago

ADMA Biologics Inc (ADMA) Hits Fresh High: Is There Still Room to Run?

Vericel Stock Sees RS Rating Shoot Higher

Investor's Business Daily

6 days ago

Vericel Stock Sees RS Rating Shoot Higher

What Makes Exelixis (EXEL) a Strong Momentum Stock: Buy Now?

Zacks

6 days ago

What Makes Exelixis (EXEL) a Strong Momentum Stock: Buy Now?

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

Zacks

6 days ago

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

MT Newswires

10 days ago

Exelixis Insider Sold Shares Worth $3,394,510, According to a Recent SEC Filing

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November

Business Wire

10 days ago

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November

Here's Why Exelixis (EXEL) is a Strong Value Stock

Zacks

10 days ago

Here's Why Exelixis (EXEL) is a Strong Value Stock

Argus Research

12 days ago

EXEL: Rating decreased to a HOLD

Here is Why Growth Investors Should Buy Exelixis (EXEL) Now

Zacks

12 days ago

Here is Why Growth Investors Should Buy Exelixis (EXEL) Now

Earnings Estimates Rising for Exelixis (EXEL): Will It Gain?

Zacks

12 days ago

Earnings Estimates Rising for Exelixis (EXEL): Will It Gain?

EXEL vs. CSLLY: Which Stock Should Value Investors Buy Now?

Zacks

12 days ago

EXEL vs. CSLLY: Which Stock Should Value Investors Buy Now?

Exelixis (EXEL) Reliance on International Sales: What Investors Need to Know

Zacks

13 days ago

Exelixis (EXEL) Reliance on International Sales: What Investors Need to Know

3 Magnificent Stocks Under $100 to Buy in November

Motley Fool

14 days ago

3 Magnificent Stocks Under $100 to Buy in November

Exelixis, Inc. Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next

Simply Wall St.

16 days ago

Exelixis, Inc. Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next

Morningstar Research

17 days ago

Analyst Report: Exelixis, Inc.

Exelixis price target raised to $36 from $33 at Piper Sandler

TipRanks

17 days ago

Exelixis price target raised to $36 from $33 at Piper Sandler

Morningstar Research

18 days ago

Analyst Report: Exelixis, Inc.

Thomson Reuters StreetEvents

18 days ago

Q3 2024 Exelixis Inc Earnings Call

Exelixis Beats on Q3 Earnings and Sales, Raises Annual Outlook

Zacks

18 days ago

Exelixis Beats on Q3 Earnings and Sales, Raises Annual Outlook

Exelixis Inc (EXEL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

GuruFocus.com

19 days ago

Exelixis Inc (EXEL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Morningstar Research

19 days ago

Analyst Report: Exelixis, Inc.

Exelixis (EXEL) Q3 2024 Earnings Call Transcript

Motley Fool

19 days ago

Exelixis (EXEL) Q3 2024 Earnings Call Transcript

Exelixis (EXEL) Reports Q3 Earnings: What Key Metrics Have to Say

Zacks

19 days ago

Exelixis (EXEL) Reports Q3 Earnings: What Key Metrics Have to Say

MT Newswires

19 days ago

Exelixis Q3 Non-GAAP Earnings, Revenue Rise; Updates Guidance

Exelixis (EXEL) Q3 Earnings and Revenues Beat Estimates

Zacks

19 days ago

Exelixis (EXEL) Q3 Earnings and Revenues Beat Estimates

Associated Press Finance

19 days ago

Exelixis: Q3 Earnings Snapshot

Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Business Wire

19 days ago

Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma

Zacks

24 days ago

Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

Zacks

24 days ago

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright

Zacks

24 days ago

5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright

Here's Why Exelixis (EXEL) is a Great Momentum Stock to Buy

Zacks

25 days ago

Here's Why Exelixis (EXEL) is a Great Momentum Stock to Buy

Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy?

Zacks

25 days ago

Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy?

1 No-Brainer Stock to Buy With $40

Motley Fool

25 days ago

1 No-Brainer Stock to Buy With $40

Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?

Zacks

a month ago

Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

Zacks

a month ago

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

EXEL or CSLLY: Which Is the Better Value Stock Right Now?

Zacks

a month ago

EXEL or CSLLY: Which Is the Better Value Stock Right Now?

Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More

Zacks

a month ago

Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More

Exelixis (EXEL) Soars 8.6%: Is Further Upside Left in the Stock?

Zacks

a month ago

Exelixis (EXEL) Soars 8.6%: Is Further Upside Left in the Stock?

Exelixis Gets Favorable Ruling in Patent Litigation With MSN

Zacks

a month ago

Exelixis Gets Favorable Ruling in Patent Litigation With MSN

MT Newswires

a month ago

Morgan Stanley Lifts Price Target on Exelixis to $30 From $28, Keeps Equalweight Rating

MT Newswires

a month ago

RBC Raises Price Target on Exelixis to $34 From $30, Keeps Outperform Rating

Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024

Business Wire

a month ago

Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024

Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories

Business Wire

a month ago

Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories

Exelixis, MRK Collaborate for Combination Studies on HNSCC and RCC

Zacks

a month ago

Exelixis, MRK Collaborate for Combination Studies on HNSCC and RCC

Exelixis and MSD to trial cancer therapies together in clinical collaboration

Clinical Trials Arena

a month ago

Exelixis and MSD to trial cancer therapies together in clinical collaboration

MT Newswires

a month ago

Exelixis, Merck Partner for Trials of Cancer Combination Therapies

Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma

Business Wire

a month ago

Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma

MT Newswires

a month ago

Morgan Stanley Lifts Price Target on Exelixis to $28 From $26, Keeps Equalweight Rating

ONCOLOGY COMMERCIALIZATION LEADER P.J. HALEY TO JOIN NETRAMARK BOARD OF DIRECTORS

CNW Group

a month ago

ONCOLOGY COMMERCIALIZATION LEADER P.J. HALEY TO JOIN NETRAMARK BOARD OF DIRECTORS

Argus Research

a month ago

EXEL: Rating increased to a BUY

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Zacks

a month ago

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Exelixis Gains 20.7% in Three Months: Is This the Right Time to Buy?

Zacks

a month ago

Exelixis Gains 20.7% in Three Months: Is This the Right Time to Buy?

MT Newswires

a month ago

RBC Raises Price Target on Exelixis to $30 From $27, Keeps Outperform Rating

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Zacks

a month ago

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

EXEL vs. CSLLY: Which Stock Is the Better Value Option?

Zacks

2 months ago

EXEL vs. CSLLY: Which Stock Is the Better Value Option?

2 Growth Stocks to Buy With Less Than $100

Motley Fool

2 months ago

2 Growth Stocks to Buy With Less Than $100

MT Newswires

2 months ago

Exelixis Insider Sold Shares Worth $659,500, According to a Recent SEC Filing

Exelixis, Inc.'s (NASDAQ:EXEL) institutional investors lost 4.0% over the past week but have profited from longer-term gains

Simply Wall St.

2 months ago

Exelixis, Inc.'s (NASDAQ:EXEL) institutional investors lost 4.0% over the past week but have profited from longer-term gains

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

Zacks

2 months ago

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

MT Newswires

2 months ago

Exelixis Faces 'Modest Growth' Prospects, Patent Risk With Limited Near-Term Upside, UBS Says

MT Newswires

2 months ago

UBS Initiates Exelixis at Neutral

Here's Why Exelixis (EXEL) is a Strong Value Stock

Zacks

2 months ago

Here's Why Exelixis (EXEL) is a Strong Value Stock

Ipsen shelves Cabometyx combo in prostate cancer after Phase III miss

Pharmaceutical Technology

2 months ago

Ipsen shelves Cabometyx combo in prostate cancer after Phase III miss

Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine

Business Wire

2 months ago

Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine

Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024

Business Wire

2 months ago

Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024

Exelixis, Inc. (EXEL): Among Hedge Funds’ Top Biotech Stock Picks

Insider Monkey

2 months ago

Exelixis, Inc. (EXEL): Among Hedge Funds’ Top Biotech Stock Picks

Exelixis (EXEL) Down 3.4% Since Last Earnings Report: Can It Rebound?

Zacks

2 months ago

Exelixis (EXEL) Down 3.4% Since Last Earnings Report: Can It Rebound?

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

Zacks

2 months ago

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

Zacks.com featured highlights Genpact, MPLX, Exelixis, Paramount Global and H&R Block

Zacks

3 months ago

Zacks.com featured highlights Genpact, MPLX, Exelixis, Paramount Global and H&R Block

EXEL vs. CSLLY: Which Stock Should Value Investors Buy Now?

Zacks

3 months ago

EXEL vs. CSLLY: Which Stock Should Value Investors Buy Now?

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

Zacks

3 months ago

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

5 Top-Ranked Value Stocks With Discounted PEG Ratio to Buy

Zacks

3 months ago

5 Top-Ranked Value Stocks With Discounted PEG Ratio to Buy

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September

Business Wire

3 months ago

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September

Has Exelixis, Inc.'s (NASDAQ:EXEL) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Simply Wall St.

3 months ago

Has Exelixis, Inc.'s (NASDAQ:EXEL) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Argus Research

3 months ago

EXEL: Lowering target price to $27.00

Why Exelixis (EXEL) Might be Well Poised for a Surge

Zacks

3 months ago

Why Exelixis (EXEL) Might be Well Poised for a Surge

Argus Research

3 months ago

EXEL: What does Argus have to say about EXEL?

Insider Sale: Director Maria Freire Sells 8,250 Shares of Exelixis Inc (EXEL)

GuruFocus.com

3 months ago

Insider Sale: Director Maria Freire Sells 8,250 Shares of Exelixis Inc (EXEL)

Exelixis Earnings Drive Share Growth

FX Empire

3 months ago

Exelixis Earnings Drive Share Growth

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Zacks

3 months ago

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

EXEL or CSLLY: Which Is the Better Value Stock Right Now?

Zacks

3 months ago

EXEL or CSLLY: Which Is the Better Value Stock Right Now?

Exelixis (EXEL) Gains 14.9% in a Week on Strong Q2 Results

Zacks

3 months ago

Exelixis (EXEL) Gains 14.9% in a Week on Strong Q2 Results

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Zacks

3 months ago

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

ADMA Biologics Inc (ADMA) Hits Fresh High: Is There Still Room to Run?

Zacks

3 months ago

ADMA Biologics Inc (ADMA) Hits Fresh High: Is There Still Room to Run?

MT Newswires

3 months ago

Exelixis Insider Sold Shares Worth $3,398,750, According to a Recent SEC Filing

Investing in Exelixis (EXEL)? Don't Miss Assessing Its International Revenue Trends

Zacks

3 months ago

Investing in Exelixis (EXEL)? Don't Miss Assessing Its International Revenue Trends

MT Newswires

3 months ago

Exelixis Insider Sold Shares Worth $2,375,000, According to a Recent SEC Filing

MT Newswires

3 months ago

Exelixis Insider Sold Shares Worth $2,077,600, According to a Recent SEC Filing

Morningstar Research

3 months ago

Analyst Report: Exelixis, Inc.

Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review

Investor's Business Daily

3 months ago

Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review

Is Caligan Partners Bullish on Exelixis Inc (EXEL) Right Now?

Insider Monkey

3 months ago

Is Caligan Partners Bullish on Exelixis Inc (EXEL) Right Now?

Does Exelixis (NASDAQ:EXEL) Deserve A Spot On Your Watchlist?

Simply Wall St.

3 months ago

Does Exelixis (NASDAQ:EXEL) Deserve A Spot On Your Watchlist?

MT Newswires

3 months ago

Truist Securities Lifts Exelixis' Price Target to $33 From $32, Keeps Buy Rating

Exelixis (EXEL) Q2 Earnings Beat, Milestone Payments Fuel Revenues

Zacks

3 months ago

Exelixis (EXEL) Q2 Earnings Beat, Milestone Payments Fuel Revenues

MT Newswires

3 months ago

Update: Exelixis Shares Rise After Higher Q2 Results

Exelixis (EXEL) Q2 2024 Earnings Call Transcript

Motley Fool

3 months ago

Exelixis (EXEL) Q2 2024 Earnings Call Transcript

Exelixis (EXEL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks

3 months ago

Exelixis (EXEL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Exelixis (EXEL) Tops Q2 Earnings and Revenue Estimates

Zacks

3 months ago

Exelixis (EXEL) Tops Q2 Earnings and Revenue Estimates

MT Newswires

3 months ago

Exelixis Q2 Non-GAAP Earnings, Revenue Rise; 2024 Revenue Guidance Updated -- Shares Up After Hours

Share on Social Networks: